Indirect Impact of Ten-valent Pneumococcal Conjugate Vaccine Program on Reducing Antimicrobial Use and Tympanostomy Tube Placements in Finland

被引:5
作者
Palmu, Arto A. [1 ]
Rinta-Kokko, Hanna [2 ]
Nohynek, Hanna [3 ]
Nuorti, J. Pekka [3 ,4 ]
机构
[1] Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, Tampere, Finland
[2] Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, Helsinki, Finland
[3] Finnish Inst Hlth & Welf, Dept Hlth Secur, Helsinki, Finland
[4] Univ Tampere, Sch Hlth Sci, Dept Epidemiol, Tampere, Finland
关键词
Streptococcus pneumoniae; conjugate vaccine; 10-valent; herd effect; antibiotic; ventilation tube; otitis media; infant; HAEMOPHILUS-INFLUENZAE; OTITIS-MEDIA; PROTEIN-D; DOUBLE-BLIND; PHID-CV10; INSERTION; CHILDREN; DISEASE; RATES; TIME;
D O I
10.1097/INF.0000000000002696
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Acute otitis media (AOM) is the most common reason for antimicrobial use, and tympanostomy tube placement (TTP) is the most common reason for surgery requiring general anesthesia in children. Ten-valent pneumococcal conjugate vaccine (PCV10) was introduced in Finland in 2010 for infants. We evaluated the indirect impact of PCV10 on these surrogate otitis outcomes in unvaccinated children. Methods: Using before-after design, unvaccinated children ineligible for National Vaccination Program (born January 2006 to May 2010) were followed-up during 2012-2016 (target cohort, age 1.5-7 years). The target cohort was compared with an age- and season-matched unvaccinated reference cohort (born January 2000 to May 2004) during 2006-2010. Antimicrobial purchase data were obtained from the Social Insurance Institution of Finland benefits register. We assessed the relative reduction by generalized Cox regression for outpatient purchases of antibiotics recommended for treatment of AOM in the Finnish guidelines. Data on all TTP procedures were obtained from national hospital discharge register and Social Insurance Institution benefits register. Results: The rate of outpatient purchases of antimicrobials recommended for AOM was 51 in the unvaccinated reference cohort and 44/100 person-years in the unvaccinated target cohort; relative rate reduction was 14.7% [95% confidence interval: 14.0-15.3] and absolute rate reduction 7/100 person-years. The rates of TTP in the reference and target cohorts were 1.66/100 and 1.61/100 person-years, respectively. The relative rate reduction was 3.6% (0.7-6.5). Conclusions: Antimicrobial use and TTP procedures reduced in unvaccinated children after PCV10 introduction in infants. These indirect effects contribute to the savings in health care resource use for otitis and may also help in combating antimicrobial resistance.
引用
收藏
页码:862 / 866
页数:5
相关论文
共 49 条
[31]   Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use [J].
Baxter, Roger ;
Aukes, Laurie ;
Pelton, Stephen, I ;
Yee, Arnold ;
Klein, Nicola P. ;
Gruber, William C. ;
Scott, Daniel A. ;
Center, Kimberly J. .
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (02) :141-150
[32]   Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial [J].
Kandasamy, Rama ;
Gurung, Meeru ;
Thorson, Stephen ;
Yu, Ly-Mee ;
Galal, Ushma ;
Voysey, Merryn ;
Kelly, Sarah ;
Wahl, Brian ;
Berbers, Guy ;
Finnegan, Kier ;
Ansari, Imran ;
Paudel, Krishna ;
Murdoch, David R. ;
O'Brien, Katherine L. ;
Kelly, Dominic F. ;
Goldblatt, David ;
Shrestha, Shrijana ;
Pollard, Andrew J. .
LANCET INFECTIOUS DISEASES, 2019, 19 (02) :156-164
[33]   Impact of private use of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal carriage among Portuguese children living in urban and rural regions [J].
Felix, Sofia ;
Handem, Sara ;
Nunes, Sonia ;
Paulo, Ana Cristina ;
Candeias, Catarina ;
Valente, Carina ;
Simoes, Alexandra S. ;
Almeida, Sonia T. ;
Tavares, Debora A. ;
Brito-Avo, Antonio ;
de Lencastre, Herminia ;
Sa-Leao, Raquel .
VACCINE, 2021, 39 (32) :4524-4533
[34]   A Dynamic Model to Estimate the Budget Impact of a Pneumococcal Vaccination Program in a 65 Year-old immunocompetent Spanish Cohort with 13 Valent Pneumococcal Conjugate Vaccine [J].
Lorente Antonanzas, Reyes ;
Varona Malumbres, Juan Luis ;
Antonanzas Villar, Fernando ;
Rejas Gutierrez, Javier .
REVISTA ESPANOLA DE SALUD PUBLICA, 2016, 90
[35]   Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial [J].
Hamaluba, Mainga ;
Kandasamy, Rama ;
Upreti, Shyam R. ;
Subedi, Girl R. ;
Shrestha, Shdjana ;
Bhattarai, Shiva ;
Gurung, Meeru ;
Pradhan, Rahul ;
Voysey, Mertyn ;
Gurung, Santosh ;
Pradhan, Shachi ;
Thapa, Anushil K. ;
Mahadan, Rakesh ;
Kiran, Usha ;
Kerridge, Simon A. ;
Hinds, Jason ;
van der Klis, Fiona ;
Snape, Matthew D. ;
Murdoch, David R. ;
Kelly, Sarah ;
Kelly, Dominic F. ;
Adhikari, Neelam ;
Thorson, Stephen ;
Pollard, Andrew J. .
LANCET INFECTIOUS DISEASES, 2015, 15 (04) :405-414
[36]   Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States [J].
Prasad, Namrata ;
Stoecker, Charles ;
Xing, Wei ;
Cho, Bo-Hyun ;
Leidner, Andrew J. ;
Kobayashi, Miwako .
VACCINE, 2023, 41 (18) :2914-2921
[37]   The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Otitis Media-Related Antibiotic Use Among Young Children in Tennessee, USA [J].
Griffith, Hannah ;
Wiese, Andrew D. ;
Mitchel, Edward F., Jr. ;
Grijalva, Carlos G. .
OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (03)
[38]   Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial [J].
Licciardi, Paul Vincent ;
Temple, Beth ;
Dai, Vo Thi Trang ;
Toan, Nguyen Trong ;
Uyen, Doan ;
Nguyen, Cattram Duong ;
Phan, Thanh, V ;
Bright, Kathryn ;
Marimla, Rachel Ann ;
Balloch, Anne ;
Huu, Tran Ngoc ;
Mulholland, Kim .
LANCET INFECTIOUS DISEASES, 2021, 21 (10) :1415-1428
[39]   Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data [J].
Strutton, David R. ;
Farkouh, Raymond A. ;
Rubin, Jaime L. ;
McGarry, Lisa J. ;
Loiacono, Paul M. ;
Klugman, Keith P. ;
Pelton, Steven I. ;
Gilmore, Kristen E. ;
Weinstein, Milton C. .
BMC INFECTIOUS DISEASES, 2012, 12
[40]   Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis [J].
Andrade, Ana Lucia ;
Afonso, Eliane T. ;
Minamisava, Ruth ;
Bierrenbach, Ana Luiza ;
Cristo, Elier B. ;
Morais-Neto, Otaliba L. ;
Policena, Gabriela M. ;
Domingues, Carla M. A. S. ;
Toscano, Cristiana M. .
PLOS ONE, 2017, 12 (09)